Welcome to Episode 5 of 6; of the 8th Annual International C. diff. Post-Conference special series Sponsored by Summit Therapeutics. This year's Live Online Conference had robust dynamics as in leading annual collaborative events while focusing on Healthcare-associated infections (HAI), and the leading HAI -- Clostridioides difficile (Also known as C. diff., C. difficile, CDI, CDAD). We will hear from the following keynote speakers

Barbara McGovern, MD, ECOSPORIII: A Phase 3 Double-blind, Randomized, Placebo-controlled Trial of the Efficacy and Safety of SER-109, an Investigational Microbiome Therapeutic for the Treatment of Patients w/Recurrent Clostridioides difficile Infection (rCDI).

Glenn Tillotson, Ph.D., FRSM, FCCP, It's a Small World w/C. diff. - a One Health Perspective.

Dayle Skelly, C. diff. Survivor, A Patient's Journey.

Many of the presentation Slides are available until January 14th, 2021 on www.cdiff2020.com We hope you enjoy the presentations.